Compare Dollar General Corp. (DG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs TransMedics Group Inc — how do they compare? Dollar General Corp. trades at $120.2 (market cap $26.49B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Dollar General Corp. is far larger — about 8.5× TransMedics Group Inc's market cap, and Dollar General Corp. pays a 1.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| DG | TMDX | |
|---|---|---|
Market Cap | $26.49B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $156.26 | $150.42 |
52-Week Low | $95.94 | $61.99 |
Enterprise Value | $40.93B | $3.49B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $119.65, down 2.24% amid broader market weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, trading below analyst consensus target of $128.45. Recent earnings beats and positive cash flow trends ($395M net in 2025) support the bullish case, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages.
Outlook remains positive given 52% analyst buy ratings and projected earnings growth, but investors face margin pressure and competitive threats from Walmart and Amazon. The stock offers value characteristics with upside to price targets, though same-store sales growth and cost management will be critical for sustained performance.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
